Astria Therapeutics, Inc. (ATXS) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
ATXS EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ATXS Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export ATXS earnings history in CSV or JSON format
Free sign-in required to download data
Astria Therapeutics, Inc. (ATXS) Earnings Overview
As of May 8, 2026, Astria Therapeutics, Inc. (ATXS) reported trailing twelve-month net income of -$124M, reflecting +30.6% year-over-year growth. The company earned $-2.14 per diluted share over the past four quarters.
Looking at the long-term picture, ATXS's historical earnings data spans multiple years. The company achieved its highest annual net income of -$15,669 in fiscal 2012.
Astria Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KALV (-$210M net income), BCAB (-$60M net income, -2980.3% margin), PRAX (-$327M net income), ATXS has comparable earnings metrics. Compare ATXS vs KALV →
ATXS Earnings vs Peers
Earnings metrics vs comparable public companies
ATXS Historical Earnings Data (2012–2024)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$94M | -29.3% | -$112M | $-1.68 | - | - |
| 2023 | -$73M | -40.6% | -$83M | $-2.42 | - | - |
| 2022 | -$52M | +73.4% | -$54M | $-3.55 | - | - |
| 2021 | -$195M | -422.6% | -$195M | $-24.58 | - | - |
| 2020 | -$37M | -41.9% | -$37M | $-12.20 | - | - |
| 2019 | -$26M | -1.6% | -$27M | $-14.06 | - | - |
| 2018 | -$26M | +5.5% | -$26M | $-30.71 | - | - |
| 2017 | -$27M | +24.1% | -$27M | $-75.73 | -5472.8% | -5418.8% |
| 2016 | -$36M | -10.5% | -$36M | $-133.31 | - | - |
| 2015 | -$33M | -49.1% | -$32M | $-243.45 | - | - |
See ATXS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATXS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATXS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonATXS — Frequently Asked Questions
Quick answers to the most common questions about buying ATXS stock.
Is ATXS growing earnings?
ATXS EPS is $-2.14, with earnings growth accelerating to +30.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-124M.
What are ATXS's profit margins?
Astria Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ATXS's earnings?
ATXS earnings data spans 2012-2024. The accelerating earnings trend is +30.6% YoY. Historical data enables comparison across business cycles.